欢迎来到天天文库
浏览记录
ID:32415282
大小:207.11 KB
页数:4页
时间:2019-02-04
《辅助内分泌治疗对i期子宫内膜癌疗效的临床观察》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、维普资讯http://www.cqvip.com·824·中国实用妇科与产科杂志2006年l1月第22卷第l1期论著文章编号:1005—2216(2006)11—0824—04辅助内分泌治疗对I期子宫内膜癌疗效的临床观察王志启,王建六,魏丽惠【摘要】目的研究辅助内分泌治疗对I期子宫内膜癌患者预后的影响。方法选取1992-01—2002—12共l】年间我院诊治I期子宫内膜癌患者105例进行回顾性研究。结果内分泌治疗组和对照组无瘤生存及总生存情况比较,差异无统计学意义(P:0.2639,P=0.2066)。内分泌治疗2、l2个月的患者则为0例,差异有统计学意义(P=0.035);二者因癌死亡患者分别为8例(11.8%)和0例,差异无统计学意义(P:0.074);二者无瘤生存及总生存情况的K—M曲线差异均有统计学意义(P=0.0163,P=0.0396)。多因素分析提示肿瘤细胞分化程度、患者年龄及内分泌治疗时间对I期子宫内膜癌患者的无瘤生存及总存活率有一定影响。结论辅助内分泌治疗l2个月或以上,可在一定程度上改善I期子宫内膜癌患者的预后。【关键词】子宫内膜癌;辅助内分泌治疗;孕激素;预后中图分类号:R71文献标志码:AAclinicalanalysisoftheefectsofadjuvantendo3、crinetherapyforstageIendometrialcarcinoma.Zhiqi,WangJianliu,WeiLihui.CenterofGynecologicOncology,PekingUniversityPeople"sHospital,Bering100044,ChinaAbstract0bjectiveToanalyzetheeffectsofadjuvantendocrinetherapyontheprognosisofstageIendometrialcarci—noma.MethodsAretrospectivestudywascarriedouton4、105casesofstageIendometrialcarcinomawhowereadmittedtoourdepartmentfromJan.1992toDec.2002.Thepatientsweredividedintotheendocrinetherapygroup(54cases,51.4%)andthecontrolgroup(51cases,48.6%).ResultsTheratesofrecurrenceandmetastasisintheendocrinetherapygroupandthecontrolwere5.6%and13.7%respectively5、.Andtherewasnoobviousdiferenceonthedeathfromtheendometrialcarcinomarateeither,whichwere3.7%and11.8%respectively,P=0.274,P=0.153;sodidthesurvivalcurveofthem(P=0.2639,P=0.2066respectively).Theratesofrecurrenceandmetastasisofthecontrolandthepatientsreceivingadjuvantendocrinetherapylessthan12months6、was14.7%.Butitwaszeroforthepatientsreceiv—ingadjuvantendocrinetherapyreachingtoorlongerthan12months.Therewasstatisticaldifferencebetweenthem(P=0.035).Thepatientsdiedfromendometrialcarcinomawere8/68and0/37,respectively.Therewasborderlinedifferencestatistically(P=0.074).Thesurvivalcurveofthemdiff7、eredmuch(P=0.0163,P:0.0396).Multivariateanalysisshowedthatthetumorcelldifferentiation,ageandendocrinetherapydurationaffectedthetumorfreesurvivalandtotalsurvivalofstageIendometrialcarcinoma.ConclusionsAdjuvantendocrinetherapynoless
2、l2个月的患者则为0例,差异有统计学意义(P=0.035);二者因癌死亡患者分别为8例(11.8%)和0例,差异无统计学意义(P:0.074);二者无瘤生存及总生存情况的K—M曲线差异均有统计学意义(P=0.0163,P=0.0396)。多因素分析提示肿瘤细胞分化程度、患者年龄及内分泌治疗时间对I期子宫内膜癌患者的无瘤生存及总存活率有一定影响。结论辅助内分泌治疗l2个月或以上,可在一定程度上改善I期子宫内膜癌患者的预后。【关键词】子宫内膜癌;辅助内分泌治疗;孕激素;预后中图分类号:R71文献标志码:AAclinicalanalysisoftheefectsofadjuvantendo
3、crinetherapyforstageIendometrialcarcinoma.Zhiqi,WangJianliu,WeiLihui.CenterofGynecologicOncology,PekingUniversityPeople"sHospital,Bering100044,ChinaAbstract0bjectiveToanalyzetheeffectsofadjuvantendocrinetherapyontheprognosisofstageIendometrialcarci—noma.MethodsAretrospectivestudywascarriedouton
4、105casesofstageIendometrialcarcinomawhowereadmittedtoourdepartmentfromJan.1992toDec.2002.Thepatientsweredividedintotheendocrinetherapygroup(54cases,51.4%)andthecontrolgroup(51cases,48.6%).ResultsTheratesofrecurrenceandmetastasisintheendocrinetherapygroupandthecontrolwere5.6%and13.7%respectively
5、.Andtherewasnoobviousdiferenceonthedeathfromtheendometrialcarcinomarateeither,whichwere3.7%and11.8%respectively,P=0.274,P=0.153;sodidthesurvivalcurveofthem(P=0.2639,P=0.2066respectively).Theratesofrecurrenceandmetastasisofthecontrolandthepatientsreceivingadjuvantendocrinetherapylessthan12months
6、was14.7%.Butitwaszeroforthepatientsreceiv—ingadjuvantendocrinetherapyreachingtoorlongerthan12months.Therewasstatisticaldifferencebetweenthem(P=0.035).Thepatientsdiedfromendometrialcarcinomawere8/68and0/37,respectively.Therewasborderlinedifferencestatistically(P=0.074).Thesurvivalcurveofthemdiff
7、eredmuch(P=0.0163,P:0.0396).Multivariateanalysisshowedthatthetumorcelldifferentiation,ageandendocrinetherapydurationaffectedthetumorfreesurvivalandtotalsurvivalofstageIendometrialcarcinoma.ConclusionsAdjuvantendocrinetherapynoless
此文档下载收益归作者所有